Minimal residual disease after allogeneic stem cell transplant: A comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia

Leukemia and Lymphoma

Volumn 54, Issue 12, 2013, Pages 2660-2666

  Rossi, Giovanni ^a   Carella, Angelo Michele ^a   Minervini, Maria Marta ^a   Savino, Lucia ^a   Fontana, Andrea ^b   Pellegrini, Fabio ^b   Greco, Michele Mario ^a   Merla, Emanuela ^a   Quarta, Gianni ^c   Loseto, Giacomo ^d   Capalbo, Silvana ^e   Palumbo, Gaetano ^e   Cascavilla, Nicola ^a  

^a Department of Hematology   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c PERRINO HOSPITAL   (Italy)

^d NATIONAL CANCER CENTRE   (Italy)

^e Riuniti Hospital   (Italy)

Author keywords

Acute leukemia; Allogeneic stem cell transplant; Chimerism; Minimal residual disease; Multiparametric flow cytometry; WT1

Indexed keywords

MESSENGER RNA; NEPHROBLASTOMA OVEREXPRESSED PROTEIN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER PATIENT; CANCER SURVIVAL; CHIMERA; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL;

ADOLESCENT; ADULT; CHIMERISM; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WILMS TUMOR; YOUNG ADULT;

EID: 84887248449     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.789508     Document Type: Article

References (41)

1. Schnittger S, Weisser M, Schoch C, et al . New score predicting for prognosis in PML-RARA-, AML-ETO, or CBFB-MYH 11-acute myeloid leukemia based on quantifi cation of fusion transcripts . Blood 2003 ; 102 : 2746-2755
2. Ommen HB, Schnittger S, Jovanovic JV, et al . Strikingly diff erent molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias . Blood 2010 ; 115 : 198-205 .
3. Cloos J, Goermans BF, Hess CJ . Stability and prognostic infl uence of FLT3 mutations in paired initial and relapsed AML samples . Leukemia 2006 ; 20 : 1217-1220 .
4. Garg M, M oore H, T obal K, et a l. P rognostic signifi cance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia . Br J Haematol 2003 ; 123 : 49-59 .
5. Ostergaard M, Olsen LH, Hasle H, et al . WT1 gene expression:an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single centre study . Br J Haematol 2004 ; 125 : 590-600 .
6. Valkova V, Polak J, Markova M, et al . Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in fi rst remission of acute myeloid leukemia has an impact on their future prognosis . Clin Transplant 2013 ; 27 : E21-E29 .
7. Ogawa H, Tamaki H, Ikegame K, et al . The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia . Blood. 2003 ; 101 : 1698-1704 .
8. Cilloni D, Renneville A, Hermitte F, et al . Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratifi cation in acute myeloid leukemia:a European LeukemiaNet study . J Clin Oncol 2009 ; 27 : 5195-5201 .
9. Candoni A, Tiribelli M, Toff oletti E, et al . Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia . Eur J Haematol 2009 ; 82 : 61-68 .
10. Zhao XS, Jin S, Zhu HH, et al . Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT . Bone Marrow Transplant 2012 ; 47 : 499-507 .
11. Alonso-Dominguez JM, Tenorio M, Velasco D, et al . Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients . Cancer Genet 2012 ; 205 : 190-191 .
12. Zhao XS, Liu YR, Zhu HH, et al . Monitoring MRD with fl ow cytometry: an eff ective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation . Ann Hematol 2012 ; 91 : 183-192 .
13. Walter RB, Gooley TA, Wood BL, et al . Impact of pretransplantation minimal residual disease, as detected by multiparametric fl ow cytometry, on outcome of myeloablative hemopoietic cell transplantation for acute myeloid leukemia . J Clin Oncol 2011; 29: 1190-1197.
14. San Miguel JF, Vidriales MB, Lopez-Berges C, et al . Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifi es diff erent patient risk groups and may contribute to post induction treatment stratifi cation. Blood 2001 ; 98 : 1746-1751 .
15. Venditti A, B uccisano F, D el Poeta G, et a l. L evel of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia . Blood 2000 ; 96 : 3948-3952 .
16. Kern W, V oskova D, S choch C, et a l. d etermination of relapse risk based on assessment of minimal residual disease in unselected patients with acute myeloid leukemia . Blood 2004 ; 104 : 3078-3085 .
17. Al-Mawali A, Gillis D, Hissaria P, et al . Incidence, sensitivity, and specifi city of leukemia-associated phenotypes in acute myeloid leukemia using specifi c fi ve-color multiparameter fl ow cytometry . Am J Clin Pathol 2008 ; 129 : 934-945 .
18. Al-Mawali A, G illis D, L ewis I . The use of receiver operating characteristic analysis for detection of minimal residual disease using fi ve-color multiparameter fl ow cytometry in acute myeloid leukemia identifi es patients with high risk of relapse . Cytometry B Clin Cytom 2009 ; 76B : 91-101 .
19. Buccisano F, Maurillo L, del Principe MI, et al . Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia . Blood 2012 ; 119 : 332-341 .
20. Maurillo L, Buccisano F, Del Principe MI, et al . Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia . J Clin Oncol 2008 ; 26 : 4944-4951 .
21. Borowitz MJ, Pullen DJ, Winick N, et al . Comparison of diagnostic and relapse fl ow cytometry phenotypes in childhood lymphoblastic leukemia:implications for residual disease detection: a report from the Children' s Oncology Group . Cytometry B Clin Cytom 2005 ; 68 : 18-24 .
22. Voskova D, Schoch C, Schnittger S, et al . Stability of leukemiaassociated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic and molecular genetic fi ndings . Cytometry B Clin Cytom 2004 ; 62 : 25-38 .
23. Tomova A, Babusikova O . Shifts in expression of immunological cell markers in relapsed acute leukemia . Neoplasma 2006 ; 53 : 500-506 .
24. Bader P, K reyenberg H, H oelle W, et a l. I ncreasing mixed chimerism defi nes a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where preemptive immunotherapy may be eff ective . Bone Marrow Transplant 2004 ; 33 : 815-821 .
25. Bader P, K reyenberg H, H oelle W, et a l. I ncreasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stemcell transplantation: possible role for pre-emptive immunotherapy J Clin Oncol. 2004 ; 22 : 1696-1705 .
26. Barrios M, J imenez-Velasco A, R oman-Gomez J, et a l. C himerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia . Haematologica 2003; 88: 801-810.
27. Bornhä u ser M, O elschlaegel U, P latzbecker U, et a l. M onitoring of donor chimerism in sorted CD34-peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation . Haematologica 2009 : 94 : 1613-1617 .
28. Lamba S, Abella E, Kukuruga D, et al . Mixed hematopoietic chimerism at day 90 following allogenic myeloablative stem cell transplantation is a predictor of relapse and survival . Leukemia 2004 ; 18 : 1681-1686 .
29. Perez-Simon JA, Caballero D, Diez-Campelo M, et al . Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423-1431.
30. Lion T, Watzinger F, Preuner S, et al . The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation . Leukemia 2012 ; 26 : 1821-1828 .
31. Vardiman JW, Th iele J, Arber DA, et al . The 2008 World Health Organization (WHO) classifi cation of myeloid neoplasms and acute leukemia: rationale and important change . Blood 2009; 114: 937-951.
32. Cheson BD, Bennett JM, Kopecky KJ, et al . Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia . J Clin Oncol 2003 ; 21 : 4642-4649 .
33. Grimwade D, H ills R K, M oorman A V, et a l. R efi nement of cytogenetic classifi cation in acute myeloid leukemia: determination of prognostic signifi cance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials . Blood 2010; 116: 354-365.
34. Moorman AV . The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia . Blood Rev 2012; 26: 123-135.
35. Van Dongen JJM, Macintyre EA, Gabert JA, et al . Standardized RTPCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease . Leukemia 1999 ; 13 : 1901-1928 .
36. Kruger N, Bacher U, Bader P, et al . NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specifi c methods and strategies for monitoring relapse following allogeneic stem cell transplantation . Part I: methods, acute leukemias, and myelodisplastic syndromes. Biol Blood Marrow Transplant 2010 ; 16 : 1187-1211 .
37. Kwon M, Martinez-Laperche C, Infante M, et al . Evaluation of minimal residual disease by real-time quantitative PCR of Wilm' s tumor I expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with fl ow cytometry and chimerism . Biol Blood Marrow Transplant 2012 ; 1 : 1-8 .
38. Miyazaki T, Fujita H, Fujimaki K, et al . Clinical signifi cance of minimal residual disease detected detected by multidimensional fl ow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia . Leuk Res 2012; 36: 998-1003.
39. Rossi G, Minervini MM, Carella AM, et al . Comparison between fl ow cytometry and WT1 RNA quantifi cation in monitoring minimal residual disease in acute myeloid leukemia without specifi c molecular targets . Leuk Res 2012; 36: 401-406.
40. Rossi G, Nomdedeu JF, Minervini MM, et al . CD117-CD15 in acute myeloid leukemia: no role as LAIP in the study of minimal residual disease . Eur J Haematol 2013 ; 90 : 171-174 .
41. Van de Loosdrecht AA, Alhan C, Ben é MC, et al . Standardization of fl ow cytometry in myelodisplastic syndromes. Report from the fi rst European LeukemiaNet working conference on fl ow cytometry in myelodysplastic syndromes . Haematologica 2009 ; 94 : 1124-1134 .